Prospective Study
Copyright ©The Author(s) 2025.
World J Gastroenterol. Aug 28, 2025; 31(32): 109383
Published online Aug 28, 2025. doi: 10.3748/wjg.v31.i32.109383
Figure 1
Figure 1 Patient enrollment and sample collection. R: Resectable; BR: Borderline resectable; PDAC: Pancreatic ductal adenocarcinoma; NAT: Neoadjuvant therapy; pCR: Pathologiccaly complete response; pTis: Pathological carcinoma in situ.